Skip to main content
ACS Omega logoLink to ACS Omega
. 2021 Jan 20;6(4):3434. doi: 10.1021/acsomega.0c06294

Correction to Naringin in Combination with Isothiocyanates as Liposomal Formulations Potentiates the Anti-inflammatory Activity in Different Acute and Chronic Animal Models of Rheumatoid Arthritis

Sangeeta Mohanty , Ashish Kumar Sahoo, V Badireenath Konkimalla , Abhisek Pal, Sudam Chandra Si
PMCID: PMC7860241  PMID: 33553962

The authors would like to inform readers of the following corrections:

In Table 3, titled NAR (500 μg/mL) (689.013 μM) Encapsulation in the NAR + SFN Liposome, the micromolar value is erroneous and should be read as 861.3 μM.

Table 3. NAR (500 μg/mL) (861.3 μM) Encapsulation in the NAR + SFN Liposome.

lipid ratio (DPPC/Chol/DSPE-020CN) concentration of NAR post dialysis (μg/mL) encapsulation efficiency (%)
15:0:1 366.2 ± 14.5 73.2 ± 2.9%
15:4:1 394.6 ± 13.3 78.9 ± 2.7%
15:9:1 386.2 ± 14.9 77.2 ± 3.0%

In Table 5, titled NAR (500 μg/mL) (689.013 μM) Encapsulation in the NAR + PEITC Liposome, the micromolar value is erroneous and should be read as 861.3 μM.

Table 5. NAR (500 μg/mL) (861.3 μM) Encapsulation in the NAR + PEITC Liposome.

lipid ratio (DPPC/Chol/DSPE-020 CN) concentration of NAR post dialysis (μg/mL) encapsulation efficiency (%)
15:0:1 370.9 ± 23.3 74.2 ± 4.7%
15:4:1 395.4 ± 15.4 79.1 ± 3.1%
15:9:1 380.3 ± 17.4 76.1 ± 3.5%

Articles from ACS Omega are provided here courtesy of American Chemical Society

RESOURCES